Inovio Pharmaceuticals
Develops DNA medicines and CELLECTRA devices, led by INO-3107 for recurrent respiratory papillomatosis.
Something off on this page? Send us feedback.
Profile
Develops DNA medicines and CELLECTRA delivery devices for a clinical-stage pipeline in HPV-related diseases, cancer and infectious diseases. INO-3107 for recurrent respiratory papillomatosis is the lead regulatory program, with additional financing needed for development beyond it and future commercialization.
Develops DNA medicines for HPV-related diseases, cancer and infectious diseases, using investigational CELLECTRA devices to deliver DNA into cells. The platform is designed to generate T-cell responses and may also support monoclonal-antibody production and protein expression. These programs remain a development platform and pipeline, rather than established product sales.
INO-3107, an investigational treatment for adults with recurrent respiratory papillomatosis, is the lead regulatory program; its biologics license application is under FDA review for accelerated approval. FDA has identified a potential issue regarding the information supporting eligibility for that pathway, while further development beyond INO-3107 and any future commercialization require additional financing.
Company facts
Key statistics
Year to date −23.7% · Average volume (30d) 5.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jefferies | Upgrade | Positive | Buy | $3 |
| Jun 1, 2026 | H.C. Wainwright | Target | $2.50 | ||
| Nov 14, 2025 | Piper Sandler | Reiterate | Overweight | $6 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.22 | −$0.07 | +67.7% | $533.3K | — | — | +16.90% |
| May 13, 2026Q1 FY26 | −$0.30 | −$0.28 | +6.7% | $333.3K | — | — | +1.49% |
| Mar 12, 2026Q4 FY25 | −$0.37 | $0.31 | +183.8% | $333.3K | — | — | −1.19% |
| Nov 10, 2025Q3 FY25 | −$0.51 | −$0.44 | +13.7% | — | — | — | −6.98% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $65.3K | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $65.3K | −$741.7K | $0 | −$754.1K | −$745.5K | $0 | |
| Operating income | −$25.1M | −$23.1M | −$21.2M | −$17.5M | −$21.9M | −$18.6M | |
| Net income | −$19.7M | −$23.5M | −$45.5M | $3.8M | −$19.7M | −$6.0M | |
| Diluted EPS | −$725.11 | −$0.61 | −$0.87 | $0.05 | −$0.28 | −$0.07 | |
| Gross margin | 100.0% | — | — | — | — | — | |
| Operating margin | -38,337.0% | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $1.8M · FY22 $10.3M · FY23 $832.0K · FY24 $217.8K · FY25 $65.3K
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $36.7M · Total debt $8.0M · Total assets $49.4M · Shareholders' equity $4.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 69.09M · Float —
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 10.67M | 9.90% | 13G | Aug 7, 2026 |
| FMR LLC | 8.45M | 12.24% | 13F | Aug 13, 2026 |
| Janus Henderson Group PLC | 6.67M | 9.99% | 13G | Dec 8, 2025 |
| Highbridge Capital Management LLC | 6.19M | 8.20% | 13G | May 15, 2026 |
| Jupiter Topco LLC | 5.17M | 7.48% | 13F | Aug 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Precigen
FDA-approved adult RRP therapy with HPV cancer programs
- PDS Biotechnology
Pivotal HPV16-positive head-and-neck cancer immunotherapy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | $1.29 | 0.00% | $89.1M | — | — | — | — |
| Precigen | $6.97 | +0.50% | $2.48B | — | 13.2 | 28.9 | +6,322.7% |
| PDS Biotechnology | $0.2136 | +2.05% | $11.8M | — | — | — | — |
| Median | — | 13.2 | 28.9 | +6,322.7% |